Caxton Associates (UK)’s Vir Biotechnology VIR Stock Holding History

Caxton Associates (UK)’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,527	Closed	-$112K	–	980
2026 Q1	$112K	Buy	+12,527	New	+$99.8K	﹤0.01%	745

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Caxton Associates (UK)'s VIR Position: Q2 2026 in Review

Caxton Associates (UK) sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 12,527 shares — an estimated $112K sold.

Caxton Associates (UK) first reported a position in VIR in Q1 2026 and held it in 1 quarter. The position peaked at $112K in Q1 2026. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Caxton Associates (UK) reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Caxton Associates (UK) sold 12,527 Vir Biotechnology shares in Q2 2026, an estimated $112K.
Caxton Associates (UK) first reported a position in Vir Biotechnology in Q1 2026 and held it in 1 quarter.
Caxton Associates (UK)'s Vir Biotechnology position peaked at $112K in Q1 2026.
238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.